Paying users zone. Data is hidden behind: .
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. pages available today for free:
Analysis of Solvency Ratios
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Bristol-Myers Squibb Co., solvency ratios
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to equity ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to equity ratio (including operating lease liability) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to capital ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to capital ratio (including operating lease liability) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co.’s debt to assets ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Bristol-Myers Squibb Co.’s debt to assets ratio (including operating lease liability) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s financial leverage ratio increased from 2018 to 2019 and from 2019 to 2020. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.’s interest coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co.’s fixed charge coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to Equity
Bristol-Myers Squibb Co., debt to equity calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Total Bristol-Myers Squibb Company shareholders’ equity | ||||||
Solvency Ratio | ||||||
Debt to equity1 | ||||||
Benchmarks | ||||||
Debt to Equity, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Debt to Equity, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Debt to Equity, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Debt to equity = Total debt ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to equity ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to Equity (including Operating Lease Liability)
Bristol-Myers Squibb Co., debt to equity (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Current operating lease liabilities | ||||||
Non-current operating lease liabilities | ||||||
Total debt (including operating lease liability) | ||||||
Total Bristol-Myers Squibb Company shareholders’ equity | ||||||
Solvency Ratio | ||||||
Debt to equity (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Debt to Equity (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Debt to Equity (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to equity ratio (including operating lease liability) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to Capital
Bristol-Myers Squibb Co., debt to capital calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Total Bristol-Myers Squibb Company shareholders’ equity | ||||||
Total capital | ||||||
Solvency Ratio | ||||||
Debt to capital1 | ||||||
Benchmarks | ||||||
Debt to Capital, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Debt to Capital, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Debt to Capital, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to capital ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to Capital (including Operating Lease Liability)
Bristol-Myers Squibb Co., debt to capital (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Current operating lease liabilities | ||||||
Non-current operating lease liabilities | ||||||
Total debt (including operating lease liability) | ||||||
Total Bristol-Myers Squibb Company shareholders’ equity | ||||||
Total capital (including operating lease liability) | ||||||
Solvency Ratio | ||||||
Debt to capital (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Debt to Capital (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Debt to Capital (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to capital ratio (including operating lease liability) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to Assets
Bristol-Myers Squibb Co., debt to assets calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets1 | ||||||
Benchmarks | ||||||
Debt to Assets, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Debt to Assets, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Debt to Assets, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co.’s debt to assets ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to Assets (including Operating Lease Liability)
Bristol-Myers Squibb Co., debt to assets (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Current operating lease liabilities | ||||||
Non-current operating lease liabilities | ||||||
Total debt (including operating lease liability) | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Debt to Assets (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Debt to Assets (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Bristol-Myers Squibb Co.’s debt to assets ratio (including operating lease liability) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Financial Leverage
Bristol-Myers Squibb Co., financial leverage calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Total assets | ||||||
Total Bristol-Myers Squibb Company shareholders’ equity | ||||||
Solvency Ratio | ||||||
Financial leverage1 | ||||||
Benchmarks | ||||||
Financial Leverage, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Financial Leverage, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Financial Leverage, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Financial leverage = Total assets ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s financial leverage ratio increased from 2018 to 2019 and from 2019 to 2020. |
Interest Coverage
Bristol-Myers Squibb Co., interest coverage calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings (loss) attributable to BMS | ||||||
Add: Net income attributable to noncontrolling interest | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Solvency Ratio | ||||||
Interest coverage1 | ||||||
Benchmarks | ||||||
Interest Coverage, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Interest Coverage, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Interest Coverage, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.’s interest coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Fixed Charge Coverage
Bristol-Myers Squibb Co., fixed charge coverage calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings (loss) attributable to BMS | ||||||
Add: Net income attributable to noncontrolling interest | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Add: Operating lease expense | ||||||
Earnings before fixed charges and tax | ||||||
Interest expense | ||||||
Operating lease expense | ||||||
Fixed charges | ||||||
Solvency Ratio | ||||||
Fixed charge coverage1 | ||||||
Benchmarks | ||||||
Fixed Charge Coverage, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Fixed Charge Coverage, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Fixed Charge Coverage, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co.’s fixed charge coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |